GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jazz Pharmaceuticals PLC (FRA:J7Z) » Definitions » Other Current Liabilities

Jazz Pharmaceuticals (FRA:J7Z) Other Current Liabilities : €131 Mil (As of Dec. 2023)


View and export this data going back to 2007. Start your Free Trial

What is Jazz Pharmaceuticals Other Current Liabilities?

Jazz Pharmaceuticals's other current liabilities for the quarter that ended in Dec. 2023 was €131 Mil.

Jazz Pharmaceuticals's quarterly other current liabilities increased from Jun. 2023 (€96 Mil) to Sep. 2023 (€135 Mil) but then declined from Sep. 2023 (€135 Mil) to Dec. 2023 (€131 Mil).

Jazz Pharmaceuticals's annual other current liabilities declined from Dec. 2021 (€171 Mil) to Dec. 2022 (€160 Mil) and declined from Dec. 2022 (€160 Mil) to Dec. 2023 (€131 Mil).

Jazz Pharmaceuticals Other Current Liabilities Historical Data

The historical data trend for Jazz Pharmaceuticals's Other Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jazz Pharmaceuticals Other Current Liabilities Chart

Jazz Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Current Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Jazz Pharmaceuticals Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Other Current Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Jazz Pharmaceuticals Other Current Liabilities Calculation

The liability a company needs to pay in the next 12 months, but not assigned to Accounts Payable or Debt. For instance, Wal-Mart (WMT) has accrued wages, salaries, valuation, bonuses, insurance liabilities, accrued tax etc. These are all included in other current liabilities.

Jazz Pharmaceuticals Other Current Liabilities Related Terms

Thank you for viewing the detailed overview of Jazz Pharmaceuticals's Other Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Jazz Pharmaceuticals (FRA:J7Z) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jazz Pharmaceuticals PLC (FRA:J7Z) » Definitions » Other Current Liabilities
Comparable Companies
PCVX CERE CYTK EXEL APLS ROIV ASND IONS VKTX BPMC OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX
Traded in Other Exchanges
JAZZ:USA JAZZ:Mexico
Address
Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, IRL, D04 E5W7
Website
https://www.jazzpharmaceuticals.com
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.

Jazz Pharmaceuticals (FRA:J7Z) Headlines

No Headlines